Permanent TSB Group Holdings plc (LON:PTSB)

Ligand Pharmaceuticals Income Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Interest Income on Loans	-	870	766	417	354	382
Interest Income on Investments	-	29	12	-	-	-
Total Interest Income	-	899	778	417	354	382
Interest Paid on Deposits	-	287	158	55	41	41
Net Interest Income	589	612	620	362	313	341
Net Interest Income Growth (YoY)	-6.95%	-1.29%	71.27%	15.65%	-8.21%	-4.21%
Income From Trading Activities	1	2	3	3	2	1
Other Non-Interest Income	68	58	45	48	46	33
Total Non-Interest Income	69	60	48	51	48	34
Non-Interest Income Growth (YoY)	43.75%	25.00%	-5.88%	6.25%	41.18%	-40.35%
Revenues Before Loan Losses	658	672	668	413	361	375
Provision for Loan Losses	-16	-30	56	7	-1	155
Revenue	674	702	612	406	362	220
Revenue Growth (YoY)	-0.59%	14.71%	50.74%	12.16%	64.55%	-45.41%
Occupancy Expenses	15	29	27	21	21	21
Amortization of Goodwill & Intangibles	37	62	40	31	26	15
Selling, General & Administrative	204	410	375	298	248	243
Other Non-Interest Expense	275	33	60	51	50	49
Total Non-Interest Expense	531	534	533	493	373	328
EBT Excluding Unusual Items	143	168	79	-87	-11	-108
Asset Writedown	-	-	-	1	-	-1
Legal Settlements	-6	-9	-3	-4	-15	-
Other Unusual Items	-32	2	5	370	19	-26
Pretax Income	103	159	79	267	-21	-166
Income Tax Expense	-11	-3	11	44	-1	-4
Net Income	114	162	68	223	-20	-162
Preferred Dividends & Other Adjustments	22	43	43	10	21	11
Net Income to Common	92	119	25	213	-41	-173
Net Income Growth	7.55%	138.23%	-69.51%	-	-	-
Basic Shares Outstanding	-	4,407	556	468	455	455
Diluted Shares Outstanding	-	4,407	556	468	455	455
Shares Change (YoY)	-	693.33%	18.61%	3.01%	-	-
EPS (Basic)	-	0.03	0.04	0.45	-0.09	-0.38
EPS (Diluted)	-	0.03	0.04	0.45	-0.09	-0.38
EPS Growth	-	-40.00%	-90.09%	-	-	-
Effective Tax Rate	-	-	13.92%	16.48%	-	-

Updated Mar 4, 2025. Source: S&P Global Market Intelligence. Banks template. Financial Sources.